FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Categories Cancer Treatment
Update : News from the FDA - Two new metastatic colorectal cancer treatments
Most relevant for: People with colorectal cancer
The FDA recently approved two new treatments for metastatic colorectal cancer. (Posted 3/22/24)
Read More
Topic : Progress in the treatment of triple-negative breast cancer
Most relevant for: People with triple-negative breast cancer
During the December 2023 San Antonio Breast Cancer Symposium, Dr. Melinda Telli presented a summary of research that has led to better treatments for triple-negative breast cancer (TNBC). These treatments now include drugs called targeted therapies and immunotherapies for both early and late stages of TNBC. (Posted 3/19/24)
Read More
Relevance: Medium
Update : News from the FDA– new breast cancer treatment, thermography warning and implant screening updates
Relevance: Medium
Most relevant for: People with HR-positive and HER2-negative metastatic breast cancer. People with silicone breast implants. People considering thermography screening
This XRAY review is a summary of FDA breast cancer updates from July to December 2023. This includes a new drug approval and two consumer updates. (Posted 2/21/24)
Read More
Update : New drug combination for the second treatment of some HR-positive advanced breast cancers
Most relevant for: People with hormone receptor (HR)-positive or HER2-negative breast cancer that has spread outside the breast tissue.
The FDA approved Truqap plus Faslodex for the treatment of metastatic hormone receptor-positive (HR-positive), HER2-negative breast cancer that returned or worsened after treatment with hormone therapy. The approval is for treating cancers in people whose tumors had a mutation in one of three genes. For people with one of these mutations, Truqap improved the time until their cancer came back or got worse. (Posted 2/9/24)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : Immunotherapy improves outcomes of advanced endometrial cancer
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with advanced endometrial cancer
Standard treatment for advanced endometrial cancer may soon change. A study found that people with advanced or recurrent endometrial cancer who received immunotherapy with chemotherapy had better outcomes than those who had chemotherapy alone. (Posted 12/4/23)
Este artículo está disponible en español.
Read More
Update : New drug combination approved for treatment of BRCA-mutated metastatic prostate cancer
Most relevant for: People with metastatic castration resistant prostate cancer with a mutation in BRCA1 or BRCA2
The FDA approved Akeega (niraparib and abiraterone) plus prednisone for the treatment of BRCA-mutated, metastatic castration-resistant prostate cancer (mCRPC). Akeega can be used as an early or later treatment. (Posted 11/9/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Pausing hormone therapy to pursue pregnancy does not increase the short-term risk of early-stage cancer recurrence
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: Women with breast cancer who are considering pregnancy
Women who paused hormone therapy treatment of early-stage hormone receptor-positive (HR-positive) breast cancer to attempt to get pregnant had no increase in short-term recurrence. (Posted 11/3/23)
Este artículo está disponible en español.
Read More
Update : New first-line treatment option for metastatic prostate cancer
Most relevant for: People with metastatic castration resistant prostate cancer who have an inherited or tumor mutation in certain genes.
The FDA has approved Talzenna (talazoparib) with Xtandi (enzalutamide) as first-line treatments for some patients with metastatic castration-resistant prostate cancer. (Posted 10/2/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Quality of Writing: High
Topic : Sexual health concerns of gay and bisexual men with prostate cancer
Relevance: Medium-High
Quality of Writing: High
Most relevant for: Gay and bisexual men diagnosed with prostate cancer
Prostate cancer therapy can affect gay and bisexual men differently than heterosexual men. Many urologists do not routinely address these unique concerns. Selecting providers who understand the concerns that are unique to gay and bisexual patients and asking questions about sexual health concerns may improve these patients' healthcare experiences. (Posted 9/21/23)
Este artículo está disponible en español.
Read More
Update : New drug combination for early treatment of some metastatic prostate cancer
Most relevant for: People with metastatic castration resistant prostate cancer with a mutation in BRCA1 or BRCA2
The FDA approved Lynparza (olaparib) for use earlier in treatment of metastatic castration-resistant prostate cancer (mCRPC) when added to abiraterone and prednisone for people with a BRCA mutation found through genetic or tumor testing. Lynparza combined with hormone therapy may now be used as a first-line or later treatment. (Posted 9/11/23)
Este artículo está disponible en español.
Read More